2026-04-17T12:48:07Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2203322025-12-05T14:15:24Zcom_2072_1057col_2072_478858col_2072_478906col_2072_478917col_2072_478921

A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study Pelgrim, Teuntje A. D Philipsen, Alexandra Young, Allan H. Juruena, Mario Jiménez Martínez, Ester Vieta i Pascual, Eduard, 1963- Jukić, Marin Van der Eycken, Erik Heilbronner, Urs Moldovan, Ramona Kas, Martien J.H. Jagesar, Raj R. Nöthen, Markus M. Hoffmann, Per Shomron, Noam Kilarski, Laura L. van Amelsvoort, Therese Campforts, Bea van Westrhenen, Roos Trastorn bipolar Depressió psíquica Ansietat Medicina personalitzada Esquizofrènia Psicosi Salut mental Manic-depressive illness Mental depression Anxiety Personalized medicine Schizophrenia Psychoses Mental health Background: Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. Methods: This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. Conclusions: This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines. 2025-04-08T11:51:36Z 2025-04-08T11:51:36Z 2024-02-01 2025-04-08T11:51:37Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 1424-8247 https://hdl.handle.net/2445/220332 746255 38399366 eng Reproducció del document publicat a: https://doi.org/10.3390/ph17020151 Pharmaceuticals, 2024, vol. 17, num.2 https://doi.org/10.3390/ph17020151 cc-by (c) Pelgrim, T.A.D. et al., 2024 http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess 15 p. application/pdf MDPI Articles publicats en revistes (Medicina)